Stocks and Investing Stocks and Investing
Mon, August 12, 2024
Fri, August 9, 2024

Colin Bristow Maintained (BTAI) at Hold with Decreased Target to $1 on, Aug 9th, 2024


Published on 2024-10-28 13:32:14 - WOPRAI, Colin Bristow
  Print publication without navigation


Colin Bristow of UBS, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Hold with Decreased Target from $3.5 to $1 on, Aug 9th, 2024.

Colin has made no other calls on BTAI in the last 4 months.



There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 0 agree with Colin's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Colin


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $7 on, Thursday, August 8th, 2024
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy and Held Target at $7 on, Thursday, June 27th, 2024
Contributing Sources